BioCentury | Apr 30, 2012
Product Development

Beyond statins: LDL diversity

...product last year from Nano Terra Inc. , which obtained it through its acquisition of Surface Logix Inc....
BioCentury | May 2, 2011
Company News

Kadmon Pharmaceuticals LLC, Nano Terra deal

...or royalty fees. Nano Terra gained the products and technology through its April acquisition of Surface Logix Inc....
BioCentury | Apr 25, 2011
Company News

Kadmon acquires Nano Terra compounds

...cancer and autoimmune diseases. Nano Terra gained the products and technology through its acquisition of Surface Logix Inc....
BioCentury | Apr 18, 2011
Company News

Nano Terra, Surface Logix deal

...will acquire Surface Logix for an undisclosed cash sum. The deal gives Nano Terra access to Surface Logix's...
...Pharmacomer drug discovery technology. Further terms were not disclosed. Nano Terra Inc. , Brighton, Mass. Surface Logix Inc....
BioCentury | Oct 14, 2010
Targets & Mechanisms

A new boost from sildenafil

...in conjunction with doxorubicin." "The doxorubicin findings are really compelling," said Paul Sweetnam, CSO of Surface Logix Inc....
...has completed Phase IIa testing in multiple indications, including hypertension, Raynaud's disease and erectile dysfunction. Surface Logix...
...Institute , Boston, Mass. Pfizer Inc. (NYSE:PFE), New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Surface Logix Inc....
BioCentury | Aug 3, 2009
Strategy

What might fit

...II Serodus A/S Piboserod (SB 207266) Serotonin (5-HT4) receptor antagonist Treat heart failure Ph II Surface Logix Inc....
BioCentury | Mar 16, 2009
Finance

Ebb & Flow

...its approach to cancer antibody discovery and development. In between, mid-stage drug developers Relypsa and Surface Logix...
...into 2010 while it continues to explore territory-specific partnerships for RLY5016. Taking the E train Surface Logix...
BioCentury | Mar 16, 2009
Clinical News

SLx-4090: Phase IIb started

...a 3-month, double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate oral SLx-4090 in 135 patients. Surface Logix Inc....
BioCentury | Jan 26, 2009
Company News

Nabriva management update

...Vienna, Austria Business: Infectious Hired: William Prince as CMO, formerly chief development officer at Surface Logix Inc. WIR...
BioCentury | May 19, 2008
Company News

Surface Logix board of directors update

Surface Logix Inc. , Brighton, Mass. Business: Cardiovascular, Metabolic, Chemistry Appointed: Steven Gillis, a director, to executive chairman WIR Staff Cardiovascular...
Items per page:
1 - 10 of 42
BioCentury | Apr 30, 2012
Product Development

Beyond statins: LDL diversity

...product last year from Nano Terra Inc. , which obtained it through its acquisition of Surface Logix Inc....
BioCentury | May 2, 2011
Company News

Kadmon Pharmaceuticals LLC, Nano Terra deal

...or royalty fees. Nano Terra gained the products and technology through its April acquisition of Surface Logix Inc....
BioCentury | Apr 25, 2011
Company News

Kadmon acquires Nano Terra compounds

...cancer and autoimmune diseases. Nano Terra gained the products and technology through its acquisition of Surface Logix Inc....
BioCentury | Apr 18, 2011
Company News

Nano Terra, Surface Logix deal

...will acquire Surface Logix for an undisclosed cash sum. The deal gives Nano Terra access to Surface Logix's...
...Pharmacomer drug discovery technology. Further terms were not disclosed. Nano Terra Inc. , Brighton, Mass. Surface Logix Inc....
BioCentury | Oct 14, 2010
Targets & Mechanisms

A new boost from sildenafil

...in conjunction with doxorubicin." "The doxorubicin findings are really compelling," said Paul Sweetnam, CSO of Surface Logix Inc....
...has completed Phase IIa testing in multiple indications, including hypertension, Raynaud's disease and erectile dysfunction. Surface Logix...
...Institute , Boston, Mass. Pfizer Inc. (NYSE:PFE), New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Surface Logix Inc....
BioCentury | Aug 3, 2009
Strategy

What might fit

...II Serodus A/S Piboserod (SB 207266) Serotonin (5-HT4) receptor antagonist Treat heart failure Ph II Surface Logix Inc....
BioCentury | Mar 16, 2009
Finance

Ebb & Flow

...its approach to cancer antibody discovery and development. In between, mid-stage drug developers Relypsa and Surface Logix...
...into 2010 while it continues to explore territory-specific partnerships for RLY5016. Taking the E train Surface Logix...
BioCentury | Mar 16, 2009
Clinical News

SLx-4090: Phase IIb started

...a 3-month, double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate oral SLx-4090 in 135 patients. Surface Logix Inc....
BioCentury | Jan 26, 2009
Company News

Nabriva management update

...Vienna, Austria Business: Infectious Hired: William Prince as CMO, formerly chief development officer at Surface Logix Inc. WIR...
BioCentury | May 19, 2008
Company News

Surface Logix board of directors update

Surface Logix Inc. , Brighton, Mass. Business: Cardiovascular, Metabolic, Chemistry Appointed: Steven Gillis, a director, to executive chairman WIR Staff Cardiovascular...
Items per page:
1 - 10 of 42